Investor Presentaiton

Strong Commercial Fit with Oncology Portfolio KRAZATI Enhances Oncology Franchise Extending in 10 YERVOY Opdualag Diversifying beyond 10 KRAZATIⓇ (adagrasib) 200 mg TABLETS OPDIVO (nivolumab) TM Repotrectinib (ipilimumab) (nivolumab and relatlimab-rmbw) Injection for intravenous use | 480 mg/160 mg (PDUFA: 11/27/23) Diversifies BMS oncology portfolio 88 BMS leading oncology commercial infrastructure can accelerate KRAZATI launch Leverage BMS global commercial footprint to ensure KRAZATI helps patients worldwide Ill Bristol Myers Squibb™ Not for Product Promotional Use 8

View entire presentation